RxDoctor Payments Data

Daniel Hu, MD

Ophthalmology · Boston, MANPI 1205916442

Payments from drug & device makers

$717in general payments, 2019–2025

Across 18 payments — averaging $39.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$160
  • Novartis$115
  • Rxsight Inc$84
  • Katena Products, Inc. (dba Corza Medical)$82
  • Dompe US, Inc.$55
  • Sun Pharmaceutical Industries Inc.$54
  • plus $166 from 6 others

What the payments were for

  • Food & beverage$71399%
  • Education$41%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$717 in reported general payments places this provider in the 45th percentile of 653 ophthalmology providers in Massachusetts.

See all ophthalmology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$763,410
Medicare patients
1,884
Services billed
5,770

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine124$185,798
Bromfenac Sodium346$64,902
XiidraLifitegrast39$56,324
Prednisolone Acetate1,271$37,901
ProlensaBromfenac Sodium82$29,723
TyrvayaVarenicline Tartrate41$26,601
Cyclosporine35$14,947
MoxifloxacinMoxifloxacin Hcl749$13,583
Alphagan PBrimonidine Tartrate26$11,966
LumiganBimatoprost17$9,817
Brimonidine Tartrate190$8,742
ValacyclovirValacyclovir Hcl142$7,429
Travoprost30$6,187
Levofloxacin15$5,085
Fluorometholone68$4,959

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AlconSimbrinza$26$2,77914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 653 ophthalmology providers in Massachusetts.

Other ophthalmology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →